FACTORS ASSOCIATED WITH BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS UTILIZATION IN RHEUMATOID ARTHRITIS PATIENTS

被引：0
|
作者：
Hosseini, R. [1 ]
Brown, L. [1 ]
Rodriguez-Monguio, R. [2 ]
Seoane-Vazquez, E. [1 ]
机构：
[1] Chapman Univ, Sch Pharm, Irvine, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH101
引用
收藏
页码：S453 / S453
页数：1
相关论文
共 50 条
  • [31] Disease-modifying antirheumatic drugs and bone mass in rheumatoid arthritis
    Di Munno, O
    Delle Sedie, A
    Rossini, A
    Adamil, S
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2005, 23 (02) : 137 - 144
  • [32] Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis
    Michael T. Nurmohamed
    Ben A. C. Dijkmans
    Drugs, 2005, 65 : 661 - 694
  • [33] Conventional disease-modifying antirheumatic drugs to treat rheumatoid arthritis
    Rath, T.
    Sander, O.
    Rubbert, A.
    DRUG DEVELOPMENT RESEARCH, 2011, 72 (08) : 657 - 663
  • [34] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Xerxes Pundole
    Natalia V. Zamora
    Harish Siddhanamatha
    Heather Lin
    Jean Tayar
    Leung Cheuk Hong
    Liang Li
    Maria E. Suarez-Almazor
    Clinical Rheumatology, 2020, 39 : 787 - 794
  • [35] Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
    Emery, Paul
    Sebba, Anthony
    Huizinga, Tom W. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (12) : 1897 - 1904
  • [36] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Pundole, Xerxes
    Zamora, Natalia V.
    Siddhanamatha, Harish
    Lin, Heather
    Tayar, Jean
    Hong, Leung Cheuk
    Li, Liang
    Suarez-Almazor, Maria E.
    CLINICAL RHEUMATOLOGY, 2020, 39 (03) : 787 - 794
  • [37] Safety of biological disease-modifying antirheumatic drugs in rheumatoid arthritis
    Martinez-Mugica, Cristina
    Salgueiro, Esther
    FARMACIA HOSPITALARIA, 2022, 46 (01) : 15 - 20
  • [38] Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis
    Nurmohamed, MT
    Dijkmans, BAC
    DRUGS, 2005, 65 (05) : 661 - 694
  • [39] Factors Associated with Initial or Subsequent Choice of Biologic Disease Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis
    Jin, Yinzhu
    Desai, Rishi J.
    Liu, Jun
    Choi, Nam-Kyong
    Kim, Seoyoung
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [40] Health Resource Utilization and Associated Health Care Costs of Biologic Disease-Modifying Antirheumatic Drugs in German Patients With Psoriatic Arthritis
    Sewerin, Philipp
    Borchert, Kathrin
    Meise, Dominic
    Schneider, Matthias
    Mahlich, Joerg
    ARTHRITIS CARE & RESEARCH, 2022, 74 (09) : 1435 - 1443
12345